East Africa is set to lead regional performance, expanding at an average of 5.9 per cent in 2025–26, underpinned by continued ...

Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in ...